vs
EGAIN Corp（EGAN）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是EGAIN Corp的1.5倍（$35.5M vs $23.0M），EGAIN Corp净利率更高（10.2% vs -304.2%，领先314.4%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 2.6%），EGAIN Corp自由现金流更多（$9.9M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 1.4%）
eGain公司总部位于加利福尼亚州桑尼维尔，主营人工智能知识软件开发，助力企业实现客户体验与员工工作流程的智能化自动化升级，帮助企业提升运营效率，优化服务质量。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
EGAN vs RXRX — 直观对比
营收规模更大
RXRX
是对方的1.5倍
$23.0M
营收增速更快
RXRX
高出679.1%
2.6%
净利率更高
EGAN
高出314.4%
-304.2%
自由现金流更多
EGAN
多$57.2M
$-47.3M
两年增速更快
RXRX
近两年复合增速
1.4%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $23.0M | $35.5M |
| 净利润 | $2.3M | $-108.1M |
| 毛利率 | 73.1% | 59.8% |
| 营业利润率 | 8.9% | -304.8% |
| 净利率 | 10.2% | -304.2% |
| 营收同比 | 2.6% | 681.7% |
| 净利润同比 | 248.1% | 39.6% |
| 每股收益（稀释后） | $0.08 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EGANRXRX
| Q4 25 | $23.0M | $35.5M | ||
| Q3 25 | $23.5M | $5.2M | ||
| Q2 25 | $23.2M | $19.2M | ||
| Q1 25 | $21.0M | $14.7M | ||
| Q4 24 | $22.4M | $4.5M | ||
| Q3 24 | $21.8M | $26.1M | ||
| Q2 24 | $22.5M | $14.4M | ||
| Q1 24 | $22.4M | $13.8M |
净利润EGANRXRX
| Q4 25 | $2.3M | $-108.1M | ||
| Q3 25 | $2.8M | $-162.3M | ||
| Q2 25 | $30.9M | $-171.9M | ||
| Q1 25 | $66.0K | $-202.5M | ||
| Q4 24 | $671.0K | $-178.9M | ||
| Q3 24 | $652.0K | $-95.8M | ||
| Q2 24 | $1.5M | $-97.5M | ||
| Q1 24 | $1.5M | $-91.4M |
毛利率EGANRXRX
| Q4 25 | 73.1% | 59.8% | ||
| Q3 25 | 75.2% | -183.8% | ||
| Q2 25 | 72.7% | -4.9% | ||
| Q1 25 | 68.0% | -48.0% | ||
| Q4 24 | 70.2% | -181.4% | ||
| Q3 24 | 69.4% | 53.7% | ||
| Q2 24 | 69.3% | 36.2% | ||
| Q1 24 | 69.3% | 19.1% |
营业利润率EGANRXRX
| Q4 25 | 8.9% | -304.8% | ||
| Q3 25 | 12.1% | -3327.6% | ||
| Q2 25 | 14.0% | -916.8% | ||
| Q1 25 | 0.1% | -1297.9% | ||
| Q4 24 | 2.9% | -4042.4% | ||
| Q3 24 | 2.3% | -377.1% | ||
| Q2 24 | 5.3% | -697.4% | ||
| Q1 24 | 4.2% | -698.4% |
净利率EGANRXRX
| Q4 25 | 10.2% | -304.2% | ||
| Q3 25 | 12.0% | -3135.3% | ||
| Q2 25 | 132.8% | -894.2% | ||
| Q1 25 | 0.3% | -1373.3% | ||
| Q4 24 | 3.0% | -3935.5% | ||
| Q3 24 | 3.0% | -367.5% | ||
| Q2 24 | 6.7% | -676.6% | ||
| Q1 24 | 6.7% | -662.4% |
每股收益（稀释后）EGANRXRX
| Q4 25 | $0.08 | $-0.17 | ||
| Q3 25 | $0.10 | $-0.36 | ||
| Q2 25 | $1.09 | $-0.41 | ||
| Q1 25 | $0.00 | $-0.50 | ||
| Q4 24 | $0.02 | $-0.56 | ||
| Q3 24 | $0.02 | $-0.34 | ||
| Q2 24 | $0.05 | $-0.40 | ||
| Q1 24 | $0.05 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $83.1M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $88.8M | $1.1B |
| 总资产 | $146.8M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资EGANRXRX
| Q4 25 | $83.1M | $743.3M | ||
| Q3 25 | $70.9M | $659.8M | ||
| Q2 25 | $62.9M | $525.1M | ||
| Q1 25 | $68.7M | $500.5M | ||
| Q4 24 | $70.5M | $594.4M | ||
| Q3 24 | $67.2M | $427.6M | ||
| Q2 24 | $70.0M | $474.3M | ||
| Q1 24 | $83.0M | $296.3M |
总债务EGANRXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益EGANRXRX
| Q4 25 | $88.8M | $1.1B | ||
| Q3 25 | $83.5M | $1.0B | ||
| Q2 25 | $80.7M | $919.1M | ||
| Q1 25 | $51.6M | $933.9M | ||
| Q4 24 | $55.3M | $1.0B | ||
| Q3 24 | $55.7M | $524.6M | ||
| Q2 24 | $58.5M | $584.4M | ||
| Q1 24 | $63.9M | $401.2M |
总资产EGANRXRX
| Q4 25 | $146.8M | $1.5B | ||
| Q3 25 | $144.6M | $1.4B | ||
| Q2 25 | $148.0M | $1.3B | ||
| Q1 25 | $106.2M | $1.3B | ||
| Q4 24 | $111.3M | $1.4B | ||
| Q3 24 | $114.9M | $726.5M | ||
| Q2 24 | $127.9M | $775.9M | ||
| Q1 24 | $120.3M | $557.8M |
负债/权益比EGANRXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $10.1M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $9.9M | $-47.3M |
| 自由现金流率自由现金流/营收 | 43.0% | -133.1% |
| 资本支出强度资本支出/营收 | 1.0% | 3.5% |
| 现金转化率经营现金流/净利润 | 4.33× | — |
| 过去12个月自由现金流最近4个季度 | $17.6M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流EGANRXRX
| Q4 25 | $10.1M | $-46.1M | ||
| Q3 25 | $10.4M | $-117.4M | ||
| Q2 25 | $-4.3M | $-76.4M | ||
| Q1 25 | $2.2M | $-132.0M | ||
| Q4 24 | $6.4M | $-115.4M | ||
| Q3 24 | $954.0K | $-59.2M | ||
| Q2 24 | $-5.1M | $-82.2M | ||
| Q1 24 | $1.7M | $-102.3M |
自由现金流EGANRXRX
| Q4 25 | $9.9M | $-47.3M | ||
| Q3 25 | $10.2M | $-117.6M | ||
| Q2 25 | $-4.5M | $-79.6M | ||
| Q1 25 | $2.1M | $-133.8M | ||
| Q4 24 | $6.3M | $-116.7M | ||
| Q3 24 | $845.0K | $-63.8M | ||
| Q2 24 | $-5.2M | $-83.4M | ||
| Q1 24 | $1.7M | $-109.0M |
自由现金流率EGANRXRX
| Q4 25 | 43.0% | -133.1% | ||
| Q3 25 | 43.4% | -2272.5% | ||
| Q2 25 | -19.5% | -413.9% | ||
| Q1 25 | 10.0% | -907.4% | ||
| Q4 24 | 28.1% | -2567.7% | ||
| Q3 24 | 3.9% | -244.6% | ||
| Q2 24 | -23.0% | -578.5% | ||
| Q1 24 | 7.8% | -789.9% |
资本支出强度EGANRXRX
| Q4 25 | 1.0% | 3.5% | ||
| Q3 25 | 1.0% | 4.7% | ||
| Q2 25 | 0.9% | 16.4% | ||
| Q1 25 | 0.5% | 12.4% | ||
| Q4 24 | 0.6% | 28.6% | ||
| Q3 24 | 0.5% | 17.5% | ||
| Q2 24 | 0.2% | 8.2% | ||
| Q1 24 | 0.1% | 48.2% |
现金转化率EGANRXRX
| Q4 25 | 4.33× | — | ||
| Q3 25 | 3.70× | — | ||
| Q2 25 | -0.14× | — | ||
| Q1 25 | 33.48× | — | ||
| Q4 24 | 9.57× | — | ||
| Q3 24 | 1.46× | — | ||
| Q2 24 | -3.40× | — | ||
| Q1 24 | 1.17× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EGAN
| Transferred Over Time | $22.0M | 96% |
| Technology Service | $1.2M | 5% |
RXRX
暂无分部数据
